← Leaderboards
Mark M. Awad
Dana-Farber Cancer Inst
$878,255
Attributed
$878,255
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $363.3K · FY2020–23$500K$375K$250K$125K$0
'20
'21
'22
'23
Funding mix
By agency
NIH$878,255 · 3
By mechanism
P50$686,311 · 2
R21$191,944 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Nathanael Schiander Gray$36,761,550
- Bruce E. Johnson$13,594,149
- Rani E George$9,003,170
- Mikyung Kim$3,787,262
- Jens G Lohr$2,586,070
Others in their field
Other Emerging Leaders on “Patient Screening”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,844,404
- Lynn Briscoe · Leidos Biomedical Research, Inc.$96,600,220
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Jennifer Marie Suga · Kaiser Foundation Research Institute$32,396,809
- Bryan Faller · Decatur Memorial Hospital$29,346,991
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
Research focus
Patient ScreeningTumorFda ApprovedNon-Small-Cell Lung CarcinomaResistance DevelopmentTargeted TreatmentDrug ResistanceEnrollmentMalignant Neoplasm Of LungNext GenerationResistanceBiopsyAlk GeneResistance MutationCohortCrizotinibAnaplastic Lymphoma KinaseCancer PatientFutureGenesMalignant NeoplasmsMutantPositioning AttributeTyrosine Kinase Inhibitor